NorthWest Biotherapeutics Inc (NWBO)

[beachhyena]

What we have seen recently is the buyout of JUNO for almost $10B and they had huge issues with killing patients. JUNO is still 18 months to 2 years away from possible approval for a treatment for blood cancer only. This type of buyout as well as that of KITE demonstrates the eagerness and desperation BP are displaying just to get into the immunotherapy space. When we look at the science on display with NWBO's pipeline and the impending publication, I cannot imagine the ripples it will create through the industry if the data points towards a successful trial.
Because of this I cannot see why the PPS will not continue to rise over the coming weeks.